Compare Garmin Ltd. (GRMN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Tango Therapeutics Inc. — how do they compare? Garmin Ltd. trades at $281.37 (market cap $53.31B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Garmin Ltd. is far larger — about 14.2× Tango Therapeutics Inc.'s market cap, and Garmin Ltd. pays a 1.52% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 84 Days and Tango Therapeutics Inc. for 0 Days on average.
| GRMN | TNGX | |
|---|---|---|
Market Cap | $53.31B | $3.75B |
Volume | 778,898 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $313.16 | $32.90 |
52-Week Low | $187.10 | $7.50 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $50.82B | $2.77B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $279.72, up 4.86% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bearish technical signals but maintains robust fundamentals with 24.47% net margins and consistent revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent positive news includes product awards and institutional accumulation, though technical indicators suggest near-term resistance.
GRMN presents a mixed outlook: strong profitability and analyst consensus target of $320.25 offer 14.5% upside, but bearish technicals and high valuation ratios (P/E 28.53) pose risks. Investment appeal hinges on execution of 2026 revenue guidance ($7.7B) amid competitive pressures in consumer electronics.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
